MarketScale AEC 01/31/19: The Biggest Issue Facing Residential Construction

 

Keeping a finger on the pulse of the challenges and trends facing an industry can be vital to the success of a business. On this episode of the MarketScale AEC Podcast, we take a look at the biggest issue facing residential construction and break down some of the emerging trends in 2019.

Labor Shortages: Will They Continue?

Two months and five thousand dollars. When you talk about skilled labor shortages, those are the two numbers that’ll fit consumers hardest. That’s because it takes two months longer and costs $5,000 more to build a home right now in the midst of one of the industry’s worst skilled labor shortages. Contractors and subcontractors are having a hard time staffing their job sites. And they have to compete with higher paying jobs to keep their workforce.

“It’s a big issue. Labor shortages are perhaps the largest issue that’s impacting the residential side of the construction industry. Anywhere from 20,000 to 25,000 workers missing from the construction industry and that’s a challenge,” says Phil Crone Of the Dallas Builders Association.

On this episode of Marketscale AEC, we talk to Crone and Kent Schwickert of the National Roofing Contractors Association about three solutions they’re pursuing to help mitigate the damage from this labor shortage: Trade school recruiting, working certifications, and immigration reform.

Material Trends for 2019

What materials are grabbing a larger share of the market so far in 2019? To help us break down some of the trends we’re seeing early in the new year, we’re joined by Ian Daniels, Director of Architectural Products for Tamlyn. He helps us sort through the noise and get to the bottom of what is driving some of the trends we’re seeing in the AEC industry.

He hits on the trend of metal roofs and discusses whether the benefits are purely aesthetic or if there’s a function to them. He also discusses the increasing versatility of modular buildings and the impact of technology on the industry.

For the latest news, videos, and podcasts in the AEC Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @AECMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More